Overview

STATEMENT OF NEED

Of the estimated 80,470 new cases of non-Hodgkin lymphoma diagnosed each year in the United States, approximately 22% are follicular lymphoma (FL), an indolent, difficult-to-treat B-cell malignancy (ACS, 2022; NCCN, 2021). Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment, evolving disease subtypes, and unclear timing and duration of therapy continue to hamper patient outcomes, and multiple recurrences with available therapies are common. Additional challenges in management include a lack of consensus surrounding the optimal timing of therapy, the role of transplant, and the use of novel therapies to keep the rate of durable remissions high among patients with FL (NCCN, 2021). In this live meeting activity, expert faculty will assess current recommendations for molecular profiling that can inform individualized care plans, evaluate efficacy and safety data on emerging therapies for FL, and explain how to implement novel therapeutic strategies to optimize treatment outcomes for patients with newly diagnosed and relapsed/refractory FL.

Target Audience

Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with follicular lymphoma (FL).

Learning Objectives

• Evaluate molecular profiling recommendations that can inform personalized care plans for patients with FL
• Differentiate the mechanisms of action, efficacy, and safety of emerging agents for FL
• Assess the clinical application of novel therapeutic strategies for patients with newly diagnosed and relapsed/refractory FL 

FACULTY

Christopher R. Flowers (Chairperson)
Chair/Professor
Department of Lymphoma/Myeloma
MD Anderson Cancer Center

Loretta J. Nastoupil, MD
Deputy Chair Section Chief
Department of Lymphoma/Myeloma
MD Anderson Cancer Center

Carla Casulo, MD
Assistant Professor of Medicine
University of Rochester Medical Center

Sarah Rutherforr, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Weill Cornell Medicine

REGISTRATION

There is no fee to participate in or claim CME credit for this activity.

Provided by

Physicians

i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies.

The i3 Health planners, reviewers, and managers have nothing to disclose.

Christopher Flowers, MD, discloses that he has served as a consultant for AbbVie, AstraZeneca, Bayer, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/Janssen, Seagen, and Spectrum. He has received grants/research support from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Genentech/Roche, Gilead, Guardant, Iovance, Janssen, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, and Ziopharm.

Carla Casulo, MD, discloses that she has received grants/research support from Bristol Myers Squibb, Genentech, Gilead, and Verastem.

Loretta Nastoupil, MD, discloses that she has served as a consultant for ADC Therapeutics, Bristol Myers Squibb, Epizyme, Genentech, Gilead/Kite, Janssen, and Takeda, and that she has received grants/research support from Bristol Myers Squibb, Caribou Biosciences, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, and Takeda.

Sarah Rutherford, MD, discloses that she has served as a consultant for ADC Therapeutics, Celgene, Dova, Genmab, Karyopharm, Kite, and Seagen and that she has received grants/research support from Genentech and Karyopharm.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from BMS.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it..